Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Phase 3

Completed

Conditions: Sarcoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: brachytherapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2023-08-03

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 587

Registration Number: NCT00006734

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 235 locations

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Burkitt Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
de Novo Myelodysplastic Syndromes
Recurrent Grade 1 Follicular Lymphoma
Small Intestine Lymphoma
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Anaplastic Large Cell Lymphoma
Childhood Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: tacrolimus
Drug: mycophenolate mofetil
Genetic: polymerase chain reaction
Genetic: fluorescence in situ hybridization
Genetic: polymorphism analysis
Genetic: gene expression analysis
Radiation: total-body irradiation
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00049504

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Phase 2

Completed

Conditions: Central Nervous System Tumor
Brain Tumor

Interventions: Radiation: radiation therapy
Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: vincristine sulfate
Drug: Mesna
Procedure: therapeutic conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2019-08-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 378

Registration Number: NCT00027846

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Advocate Christ Medical Center, Oak Lawn, Illinois, United States

and more 161 locations

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 213

Registration Number: NCT00005985

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 78

Registration Number: NCT00032019

Locations: 🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
Memorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States

and more 78 locations

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020176

Locations: 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Inflammatory Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: tipifarnib
Biological: filgrastim
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00049114

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Phase 3

Completed

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: vincristine sulfate
Drug: carmustine
Drug: melphalan
Drug: cyclophosphamide
Drug: prednisone
Other: laboratory biomarker analysis
Biological: recombinant interferon alfa-2b

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 312

Registration Number: NCT00002556

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 2

Completed

Conditions: Juvenile Myelomonocytic Leukemia

Interventions: Drug: tipifarnib
Drug: isotretinoin
Drug: fludarabine phosphate
Drug: cytarabine
Radiation: radiation therapy
Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Procedure: allogeneic bone marrow transplantation
Procedure: double-unit umbilical cord blood transplantation
Procedure: umbilical cord blood transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00025038

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Biological: aldesleukin
Biological: filgrastim
Drug: cyclophosphamide
Drug: etoposide
Radiation: radiation therapy
Procedure: peripheral blood stem cell transplantation
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 206

Registration Number: NCT00002649

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy